

Resource Summary Report

Generated by [dkNET](#) on Aug 9, 2026

Ywhae^{tm2e(EUCOMM)}Wtsi

RRID:IMSR_EUMMCR:236

Type: Organism

Proper Citation

RRID:IMSR_EUMMCR:236

Organism Information

URL:

Proper Citation: RRID:IMSR_EUMMCR:236

Description: Mus musculus with name Ywhae^{tm2e(EUCOMM)}Wtsi from IMSR.

Species: Mus musculus

Notes: gene symbol note: tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein; epsilon polypeptide; mutant strain: Ywhae

Affected Gene: tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein; epsilon polypeptide

Genomic Alteration: targeted mutation 2e; Wellcome Trust Sanger Institute

Catalog Number: EUMMCR:236

Database: European Mouse Mutant Cell Repository

Database Abbreviation: EuMMCR

Availability: ES Cell

Organism Name: Ywhae^{tm2e(EUCOMM)}Wtsi

Record Creation Time: 20250513T061727+0000

Record Last Update: 20260808T055136+0000

Ratings and Alerts

No rating or validation information has been found for Ywhae^{tm2e(EUCOMM)}Wtsi.

No alerts have been found for Ywhae^{tm2e(EUCOMM)Wtsi}.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: European Mouse Mutant Cell Repository

Usage and Citation Metrics

We found 43 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Lindsay J, et al. (2026) Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma. Molecular cancer therapeutics, 25(4), 635.

Cao Y, et al. (2026) Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors. Cell reports. Medicine, 7(4), 102695.

Subramani E, et al. (2026) Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers. iScience, 29(6), 116184.

Savani MR, et al. (2026) Nitrogen metabolism profiling reveals cell state-specific pyrimidine synthesis pathway choice. Nature metabolism, 8(5), 1124.

Favours E, et al. (2026) Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(14), 3031.

Park VS, et al. (2025) Lipid Composition Alters Ferroptosis Sensitivity. Cancer research, 85(22), 4380.

Zoeller JJ, et al. (2025) Derivation of AZD5335, a Novel FR α -Targeted TOP1i-Loaded ADC, for the Treatment of FR α -Expressing Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(24), 5261.

Savani MR, et al. (2025) Nitrogen metabolism profiling reveals cell state-specific pyrimidine synthesis pathway choice. bioRxiv : the preprint server for biology.

Guillorit H, et al. (2025) Streptomycin targets tumor-initiating cells by disrupting oxidative phosphorylation. Cell chemical biology, 32(4), 570.

Lin C, et al. (2025) Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer. Cell reports, 44(6), 115792.

Dahiya UR, et al. (2025) Disrupting the interaction between androgen receptor and its coregulator WDR77 delays the growth of treatment-resistant prostate cancer. Cell reports,

44(9), 116235.

Yang Z, et al. (2025) Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma. *Cancer research communications*, 5(4), 719.

Wang Z, et al. (2024) Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery. *Nature communications*, 15(1), 2073.

Zhang D, et al. (2024) Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs. *Communications medicine*, 4(1), 87.

Chang Y, et al. (2024) Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition. *Cell reports. Medicine*, 5(10), 101752.

He T, et al. (2024) Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies. *Cancer cell*, 42(8), 1336.

Staniszewska AD, et al. (2024) Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(7), 1338.

Anselmino N, et al. (2024) Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(10), 2272.

Cerutti C, et al. (2024) IQGAP1 and NWASP promote human cancer cell dissemination and metastasis by regulating α 1-integrin via FAK and MRTF/SRF. *Cell reports*, 43(4), 113989.

Sconocchia G, et al. (2022) Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment. *Life science alliance*, 5(12).